MX2021001083A - Regimen posologico para anticuerpos biespecificos contra bcma-cd3. - Google Patents

Regimen posologico para anticuerpos biespecificos contra bcma-cd3.

Info

Publication number
MX2021001083A
MX2021001083A MX2021001083A MX2021001083A MX2021001083A MX 2021001083 A MX2021001083 A MX 2021001083A MX 2021001083 A MX2021001083 A MX 2021001083A MX 2021001083 A MX2021001083 A MX 2021001083A MX 2021001083 A MX2021001083 A MX 2021001083A
Authority
MX
Mexico
Prior art keywords
bcma
antibody construct
bispecific antibodies
dosing regimen
treatment
Prior art date
Application number
MX2021001083A
Other languages
English (en)
Inventor
Gerd Munzert
Gerhard Zugmaier
Max Topp
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of MX2021001083A publication Critical patent/MX2021001083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un constructo de anticuerpo que comprende un primer dominio que se une a BCMA y un segundo dominio que se une a CD3, para su uso en el tratamiento o mejora de una neoplasia positiva para BCMA, donde el constructo de anticuerpo se administra en una dosis específica en al menos un ciclo, donde un ciclo comprende un período específico de administración del constructo de anticuerpo. Además, la invención se refiere a un método para el tratamiento de una neoplasia positiva para BCMA que comprende administrar una cantidad específica de tal constructo de anticuerpo y el uso de tal constructo de anticuerpo para la fabricación de un medicamento para el tratamiento de una neoplasia positiva para BCMA.
MX2021001083A 2018-07-31 2019-07-30 Regimen posologico para anticuerpos biespecificos contra bcma-cd3. MX2021001083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862712357P 2018-07-31 2018-07-31
PCT/EP2019/070455 WO2020025596A1 (en) 2018-07-31 2019-07-30 Dosing regimen for bcma-cd3 bispecific antibodies

Publications (1)

Publication Number Publication Date
MX2021001083A true MX2021001083A (es) 2021-03-31

Family

ID=67513510

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001083A MX2021001083A (es) 2018-07-31 2019-07-30 Regimen posologico para anticuerpos biespecificos contra bcma-cd3.

Country Status (9)

Country Link
US (1) US20210284732A1 (es)
EP (1) EP3830122A1 (es)
JP (1) JP2021532073A (es)
AU (1) AU2019316164A1 (es)
CA (1) CA3105729A1 (es)
DE (1) DE102019120667A1 (es)
MX (1) MX2021001083A (es)
TW (1) TW202019477A (es)
WO (1) WO2020025596A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022140463A1 (en) * 2020-12-22 2022-06-30 Herzlinger Regina E Methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via rapid infusion
US20240050646A1 (en) * 2020-12-22 2024-02-15 Regina E. HERZLINGER Methods, systems, and apparatus for administering an antibody treatment via infusion
US11806507B2 (en) * 2020-12-22 2023-11-07 Regina E. HERZLINGER Methods, systems, and apparatus for administering an antibody treatment via infusion
CN116963774A (zh) 2021-01-28 2023-10-27 瑞泽恩制药公司 用于治疗细胞因子释放综合征的组合物和方法
WO2023201226A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
US20240277844A1 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447A (en) 1846-04-04 Car- wheel
US233A (en) 1837-06-14 Improvement in plows
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DE69909459T2 (de) 1998-04-21 2004-05-27 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
WO2000006605A2 (en) 1998-07-28 2000-02-10 Micromet Ag Heterominibodies
KR101229731B1 (ko) 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
ES2432792T5 (es) 2007-04-03 2023-01-16 Amgen Res Munich Gmbh Dominio de unión a CD3-épsilon específico de especies cruzadas
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
WO2012142164A1 (en) * 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
PE20141521A1 (es) 2011-08-23 2014-10-25 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
US20160257748A1 (en) 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
MA53750A (fr) * 2015-08-17 2021-09-15 Janssen Pharmaceutica Nv Anticorps anti-bcma, molécules de liaison d'antigène bispécifiques qui se lient au bcma et cd3 et leurs utilisations
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
CR20180420A (es) * 2016-02-03 2018-12-05 Amgen Inc Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t

Also Published As

Publication number Publication date
EP3830122A1 (en) 2021-06-09
TW202019477A (zh) 2020-06-01
CA3105729A1 (en) 2020-02-06
US20210284732A1 (en) 2021-09-16
JP2021532073A (ja) 2021-11-25
WO2020025596A1 (en) 2020-02-06
DE102019120667A1 (de) 2020-02-06
AU2019316164A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
MX2021001083A (es) Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
HRP20210440T1 (hr) Kombinirana terapija za rak
BR112018074155A2 (pt) anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo
HRP20191162T1 (hr) Postupci liječenja ankilozantnog spondilitisa uporabom anti-il-17 protutijela
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
CR20160319A (es) Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
MX2015007147A (es) Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab.
EA037351B8 (ru) Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
MX2020007697A (es) Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra grupo de diferenciacion 3 (cd3) y grupo de diferenciacion 20 (cd20) y sus usos.
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
JP2014111603A5 (es)
RU2017134443A (ru) Способ лечения с применением традипитанта
MX2018001263A (es) Nueva combinacion para el uso en el tratamiento del cancer.
HRP20240159T1 (hr) Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
MX2019005623A (es) Dosis y regimen para inhibidores de la interaccion hdm2-p53.
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
MX2021001221A (es) Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3.
RU2018127640A (ru) Комбинация ингибитора hdac и антитела против pd-l1 для лечения рака яичников
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
JOP20210269A1 (ar) تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها